Lixte Biotechnology updates treasury policy to allocate up to 25% to Bitcoin and other digital assets

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Board approved allocating up to 25% of corporate treasury to cryptocurrencies including Bitcoin.
Company will hold crypto assets with a fully regulated and compliant custodian.
CEO Geordan Pursglove cites long-term potential to hedge treasury and deliver shareholder returns.
Timing and size of purchases will depend on market conditions; policy retains flexibility.
Lixte is a clinical-stage biotech; treasury policy shift is a strategic capital allocation initiative.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.